MTM(SH:688029) Xin Lang Cai Jing·2025-09-09 06:21Core Viewpoint - Nanwei Medical's stock has shown significant volatility, with a year-to-date increase of 41.60% and a recent decline in trading performance, indicating potential market fluctuations and investor sentiment shifts [1][2]. Financial Performance - For the first half of 2025, Nanwei Medical achieved a revenue of 1.565 billion yuan, representing a year-on-year growth of 17.36%, while the net profit attributable to shareholders was 363 million yuan, also reflecting a growth of 17.04% [2]. - Cumulatively, since its A-share listing, Nanwei Medical has distributed a total of 885 million yuan in dividends, with 571 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders for Nanwei Medical decreased by 7.27% to 12,300, while the average number of circulating shares per person increased by 7.84% to 15,216 shares [2]. - The stock's trading activity on September 9 showed a net outflow of 17.55 million yuan in principal funds, with significant selling pressure compared to buying [1]. Company Overview - Nanwei Medical, established on May 10, 2000, and listed on July 22, 2019, specializes in the research, manufacturing, and sales of minimally invasive medical devices, with a revenue composition primarily from endoscopic consumables (77.80%) [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and consumables, and is categorized under various investment concepts including medical consumables and mid-cap stocks [1].